WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 74.10B +77.3% |
| Revenue (ttm) | 6.61B +46.7% |
| Net Income | 1.65B +38.4% |
| EPS | 1.25 +34.9% |
| Shares Out | 1.26B |
| PE Ratio | 47.26 |
| Forward PE | 31.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,053,645 |
| Average Volume | 4,993,270 |
| Open | 56.15 |
| Previous Close | 56.15 |
| Day's Range | 55.40 - 59.35 |
| 52-Week Range | 24.70 - 85.50 |
| Beta | -2.10 |
| RSI | 51.82 |
| Earnings Date | Mar 23, 2026 |
About WuXi XDC Cayman
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Lab... [Read more]
Financial Performance
In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.
Financial numbers in CNY Financial StatementsNews
US reshoring drive casts shadow over China’s contract drug makers: analyst
Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigu...